Participated · Series A · Feb 2026

Founded in May 2023 and headquartered in Misawa, Aomori Prefecture, MiRESSO is building a beryllium manufacturing and sales business based on an innovative low-temperature purification process originally spun out of QST research. The company targets the critical need for a stable domestic supply of beryllium, an essential neutron-multiplying material for commercial fusion reactors, while also offering its purification method as a technology platform for recycling and refining a wider range of mineral resources. MiRESSO is constructing the BETA (Beryllium Testing plant in Aomori) pilot plant on Pacific Metals’ site in Hachinohe, aiming to begin production during fiscal 2027. Over roughly three years since inception, the startup has raised about ¥4.48 billion in equity and approximately ¥6.68 billion when government grants are included. Funds from the latest round will accelerate pilot-plant build-out, secure raw-material supply, and enhance product quality to establish a new beryllium supply chain in Japan.

Participated · Equity · Jun 2025

Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.

Participated · Series E · Aug 2024

Interstellar Technologies is a Japanese launch-vehicle company focused on building Zero, a two-stage, methane/liquid oxygen rocket designed to place up to 1,000 kg into low Earth orbit. The firm targets Zero’s maiden flight in 2027 and has already signed eight payload customers from Japan, Singapore, South Korea, and the United States for that launch. Prior to Zero, Interstellar flew the Momo suborbital rocket seven times between 2017 and 2021, achieving three successful flights. Beyond launch, the company is advancing a formation-flying satellite system meant to create a phased-array antenna for direct-to-device communications. Financially, Interstellar has now raised a total of ¥44.6 billion after closing a ¥20.1 billion Series F round in January. The new capital will fund continued Zero development, scale up manufacturing, and support the communications satellite initiative.

Participated · Series A · Jul 2024

Founded in April 2024 as a spin-out from NTT Docomo and headquartered in Shibuya, Tokyo, RePlayce builds products that bridge secondary education and the workplace. Its flagship offering, the online "はたらく部" platform, lets students collaborate with professional coaches and peers to explore society, self-awareness and future careers; the service earned the Ministry of Economy, Trade and Industry’s 13th Career Education Award (Large Company division) Excellence Prize. The company is also launching HR高等学院, a correspondence high-school support program opening in April 2025 that emphasizes project-based learning, next-generation liberal arts and pathways to domestic and overseas universities. Additional lines include inquiry-focused curriculum development, dispatch of working-adult lecturers and operation of online schools. To date, RePlayce has supported career formation for more than 1,000 students and partners with multiple educational institutions nationwide. With fresh capital from its Series A round, management plans to enhance "はたらく部," expand school partnerships, open new HR高等学院 campuses and deepen corporate PBL collaborations.

Led · Equity · Jun 2024

AALTO, an Airbus subsidiary headquartered in Farnborough, manufactures and operates the solar-powered Zephyr High Altitude Platform Station (HAPS). The company focuses on stratospheric connectivity and earth observation services delivered from its HAPS vehicles. It secured a $100m investment from a consortium of Japanese businesses and banks to support commercialization and industrialisation. The funding underpins a strategic alliance to roll out services in Japan and across Asia, with an initial launch in Japan and a global entry-into-service targeted for 2026. Airbus Defence and Space will remain AALTO’s majority shareholder, and the company created a dedicated HAPS Services Business in 2022 to advance its market position. Executives described the transaction as a landmark step to combine technological expertise and connectivity reach to capitalise on sizeable addressable markets in connectivity and earth observation.